FDA NeuroVance XR coverage for business development, investment, and market access teams
The FDA has approved NeuroVance XR, a groundbreaking extended-release medication for pediatric ADHD, offering a new solution for effective symptom management.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
